BIODEXA PHARMACEUTICALS-ADR (BDRX) Fundamental Analysis & Valuation

NASDAQ:BDRX • US59564R8806

0.8669 USD
-0.05 (-5.15%)
At close: Mar 12, 2026
0.8295 USD
-0.04 (-4.31%)
After Hours: 3/12/2026, 8:24:38 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BDRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall BDRX gets a fundamental rating of 2 out of 10. We evaluated BDRX against 519 industry peers in the Biotechnology industry. While BDRX seems to be doing ok healthwise, there are quite some concerns on its profitability. BDRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. BDRX Profitability Analysis

1.1 Basic Checks

  • In the past year BDRX has reported negative net income.
  • BDRX had a negative operating cash flow in the past year.
  • BDRX had negative earnings in each of the past 5 years.
  • BDRX had a negative operating cash flow in each of the past 5 years.
BDRX Yearly Net Income VS EBIT VS OCF VS FCFBDRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • BDRX has a Return On Assets (-42.01%) which is in line with its industry peers.
  • The Return On Equity of BDRX (-54.45%) is better than 63.39% of its industry peers.
Industry RankSector Rank
ROA -42.01%
ROE -54.45%
ROIC N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
BDRX Yearly ROA, ROE, ROICBDRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • BDRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDRX Yearly Profit, Operating, Gross MarginsBDRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BDRX Health Analysis

2.1 Basic Checks

  • BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BDRX has been increased compared to 1 year ago.
  • BDRX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BDRX has a worse debt to assets ratio.
BDRX Yearly Shares OutstandingBDRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
BDRX Yearly Total Debt VS Total AssetsBDRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -10.84, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
  • BDRX has a Altman-Z score of -10.84. This is in the lower half of the industry: BDRX underperforms 74.76% of its industry peers.
  • BDRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.84
ROIC/WACCN/A
WACC6.52%
BDRX Yearly LT Debt VS Equity VS FCFBDRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • BDRX has a Current Ratio of 3.63. This indicates that BDRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.63, BDRX is in line with its industry, outperforming 43.16% of the companies in the same industry.
  • BDRX has a Quick Ratio of 3.63. This indicates that BDRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.63, BDRX is in line with its industry, outperforming 45.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.63
BDRX Yearly Current Assets VS Current LiabilitesBDRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BDRX Growth Analysis

3.1 Past

  • BDRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.57%, which is quite impressive.
  • BDRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)98.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.4%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 12.21% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. BDRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BDRX. In the last year negative earnings were reported.
  • Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDRX Price Earnings VS Forward Price EarningsBDRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDRX Per share dataBDRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • BDRX's earnings are expected to grow with 12.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y12.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDRX Dividend Analysis

5.1 Amount

  • No dividends for BDRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BDRX Fundamentals: All Metrics, Ratios and Statistics

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (3/12/2026, 8:24:38 PM)

After market: 0.8295 -0.04 (-4.31%)

0.8669

-0.05 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12
Earnings (Next)05-12
Inst Owners52.05%
Inst Owner Change3535.5%
Ins Owners0.39%
Ins Owner ChangeN/A
Market Cap727.16K
Revenue(TTM)N/A
Net Income(TTM)-6.23M
Analysts85.71
Price Target183.6 (21078.91%)
Short Float %2.41%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.09
EV/EBITDA N/A
EPS(TTM)-21
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)-17.67
FCFYN/A
OCF(TTM)-17.2
OCFYN/A
SpS0
BVpS18.28
TBVpS9.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.01%
ROE -54.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.63
Quick Ratio 3.63
Altman-Z -10.84
F-Score3
WACC6.52%
ROIC/WACCN/A
Cap/Depr(3y)138.58%
Cap/Depr(5y)102.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.4%
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.58%
OCF growth 3YN/A
OCF growth 5YN/A

BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ

What is the fundamental rating for BDRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to BDRX.


What is the valuation status of BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIODEXA PHARMACEUTICALS-ADR (BDRX). This can be considered as Overvalued.


What is the profitability of BDRX stock?

BIODEXA PHARMACEUTICALS-ADR (BDRX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BDRX stock?

The Earnings per Share (EPS) of BIODEXA PHARMACEUTICALS-ADR (BDRX) is expected to grow by 33.34% in the next year.